Emergent BioSolutions (EBS) Gains from Investment Securities (2014 - 2026)

Emergent BioSolutions' Gains from Investment Securities history runs 13 years deep, the most recent figure standing at -$8.4 million for Q1 2026.

• On a quarterly basis, Gains from Investment Securities rose 11.58% year-over-year to -$8.4 million in Q1 2026; TTM through Mar 2026 was -$8.4 million, a 10.64% increase from a year earlier, with the FY2024 full-year figure at $600000.0, up 200.0% from the prior year.
• Gains from Investment Securities climbed to -$8.4 million in Q1 2026 per EBS's latest filing, from -$9.5 million in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $1.3 million in Q2 2022 and bottomed at -$9.5 million in Q1 2025.
• The 5-year median for Gains from Investment Securities is $300000.0 (2023), against an average of -$1.6 million.
• Biggest YoY gain for Gains from Investment Securities was 125.0% in 2023; the steepest drop was 283.33% in 2023.
• Year by year, Gains from Investment Securities stood at -$2.4 million in 2022, then jumped by 125.0% to $600000.0 in 2023, then tumbled by 83.33% to $100000.0 in 2024, then plunged by 9600.0% to -$9.5 million in 2025, then increased by 11.58% to -$8.4 million in 2026.
• Per Business Quant, the three latest EBS Gains from Investment Securities figures stand at -$8.4 million (Q1 2026), -$9.5 million (Q1 2025), and $100000.0 (Q2 2024).